Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

94.94 -0.34 (-0.36%)

Streaming Delayed Price Updated: 3:36 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

September 23, 2025

From BioNTech SE

Via GlobeNewswire

Why BioNTech Stock Bumped Higher Today ↗

September 22, 2025

Investors were cheered by two pieces of good news concerning the biotech's most famous product.

Via The Motley Fool

CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids ↗

September 19, 2025

Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.

Via Investor's Business Daily

The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut ↗

September 18, 2025

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.

Via Investor's Business Daily

Topics Government

Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside ↗

September 08, 2025

Via Stocktwits

What Analysts Are Saying About BioNTech Stock ↗

September 08, 2025

Via Benzinga

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax ↗

September 16, 2025

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.

Via Benzinga

Oracle Retreats, Fed Rate Cut Looms, and Vaccine Politics Shake Pharma Stocks ↗

September 15, 2025

Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised...

Via Chartmill

Topics Artificial Intelligence Economy

Why Did BioNTech Stock Surge 10% Pre-Market Today? ↗

September 05, 2025

Via Stocktwits

Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population ↗

August 27, 2025

Via Stocktwits

Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio? ↗

September 14, 2025

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.

Via Benzinga

Topics Earnings

Why BioNTech Stock Sank by More Than 7% Today ↗

September 12, 2025

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..

Via The Motley Fool

Topics Death Government

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths ↗

September 12, 2025

Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths.

Via Benzinga

Topics Government

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults ↗

September 08, 2025

Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.

Via Benzinga

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗

September 08, 2025

BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.

Via Benzinga

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

Via Investor's Business Daily

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

September 08, 2025

From Pfizer Inc.

Via Business Wire

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

September 08, 2025

From BioNTech SE

Via GlobeNewswire

Why BioNTech Stock Crushed the Market Today ↗

September 05, 2025

The company might be close to commercializing its most advanced pipeline program.

Via The Motley Fool

Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday ↗

September 05, 2025

Via Benzinga

Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? ↗

September 05, 2025

It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.

Via Investor's Business Daily

BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb ↗

September 05, 2025

The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.

Via Investor's Business Daily

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data ↗

September 05, 2025

BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.

Via Benzinga

Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works ↗

September 01, 2025

Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest.

Via Benzinga

Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? ↗

August 31, 2025

Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.

Via Benzinga

RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines ↗

August 27, 2025

FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.

Via Benzinga

RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles. ↗

August 27, 2025

Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday.

Via Investor's Business Daily

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

August 27, 2025

From Pfizer Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.